ID   YCU-T891
AC   CVCL_8023
SY   YCU T891
DR   Cosmic; 1136968
DR   Cosmic; 1556188
DR   Wikidata; Q54995357
RX   PubMed=18097577;
RX   PubMed=21362583;
RX   PubMed=21631644;
RX   PubMed=26780976;
RX   PubMed=26781072;
CC   Problematic cell line: Contaminated. YCU-L891 and YCU-T891 have been shown to be identical (PubMed=26780976; PubMed=26781072).
CC   Population: Japanese.
CC   Doubling time: 14.93 hours (PubMed=21362583).
CC   HLA typing: A*24:02 (Direct_author_submission).
CC   Miscellaneous: HLA typing and STR profile from personal communication of Sano D.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,13
ST   D16S539: 8
ST   D18S51: 15,16
ST   D21S11: 30
ST   D3S1358: 18
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 21
ST   Penta D: 12,13
ST   Penta E: 9,15
ST   TH01: 7,9
ST   TPOX: 11
ST   vWA: 14,19
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_8018 ! YCU-L891
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 15
RX   PubMed=18097577; DOI=10.3892/or.19.1.65;
RA   Taguchi T., Tsukuda M., Imagawa-Ishiguro Y., Kato Y., Sano D.;
RT   "Involvement of EGFR in the response of squamous cell carcinoma of the
RT   head and neck cell lines to gefitinib.";
RL   Oncol. Rep. 19:65-71(2008).
RX   PubMed=21362583; DOI=10.1016/j.anl.2011.01.018;
RA   Sakakibara A., Tsukuda M., Kondo N., Ishiguro Y., Kimura M.,
RA   Fujita K., Takahashi H., Matsuda H.;
RT   "Examination of the optimal condition on the in vitro sensitivity to
RT   telomelysin in head and neck cancer cell lines.";
RL   Auris Nasus Larynx 38:589-599(2011).
RX   PubMed=21631644; DOI=10.1111/j.1349-7006.2011.01999.x;
RA   Kondo N., Tsukuda M., Taguchi T., Nakazaki K., Sakakibara A.,
RA   Takahashi H., Toth G., Nishimura G.;
RT   "Gene status of head and neck squamous cell carcinoma cell lines and
RT   cetuximab-mediated biological activities.";
RL   Cancer Sci. 102:1717-1723(2011).
RX   PubMed=26780976; DOI=10.3892/or.2016.4573;
RA   Sano D., Matsuda H., Ishiguro Y., Nishimura G., Kawakami M.,
RA   Tsukuda M.;
RT   "Corrigendum: Antitumor effects of IDN5109 on head and neck squamous
RT   cell carcinoma.";
RL   Oncol. Rep. 35:2494-2494(2016).
RX   PubMed=26781072; DOI=10.3892/or.2016.4574;
RA   Sano D., Kawakami M., Fujita K., Kimura M., Yamashita Y., Ishiguro Y.,
RA   Nishimura G., Matsuda H., Tsukuda M.;
RT   "Corrigendum: Antitumor effects of ZD6474 on head and neck squamous
RT   cell carcinoma.";
RL   Oncol. Rep. 35:2495-2495(2016).